Log in

NASDAQ:AMRN - Amarin Stock Price, Forecast & News

$24.12
+1.13 (+4.92 %)
(As of 12/15/2019 03:19 PM ET)
Today's Range
$23.00
Now: $24.12
$24.17
50-Day Range
$16.17
MA: $20.11
$24.21
52-Week Range
$11.78
Now: $24.12
$24.67
Volume7.75 million shs
Average Volume11.50 million shs
Market Capitalization$8.62 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.14
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$229.21 million
Book Value$0.40 per share

Profitability

Net Income$-116,440,000.00

Miscellaneous

EmployeesN/A
Market Cap$8.62 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.


Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) released its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.04) by $0.03. The biopharmaceutical company earned $112.40 million during the quarter, compared to analyst estimates of $110.04 million. Amarin had a negative return on equity of 26.67% and a negative net margin of 17.42%. Amarin's quarterly revenue was up 104.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.08) EPS. View Amarin's Earnings History.

When is Amarin's next earnings date?

Amarin is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Amarin.

What price target have analysts set for AMRN?

12 brokerages have issued 12 month price objectives for Amarin's shares. Their forecasts range from $7.00 to $51.00. On average, they expect Amarin's share price to reach $27.73 in the next twelve months. This suggests a possible upside of 15.0% from the stock's current price. View Analyst Price Targets for Amarin.

What is the consensus analysts' recommendation for Amarin?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 sell rating, 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (11/7/2019)
  • 2. HC Wainwright analysts commented, "Our PT of $51 is based on equally weighted average of: (a) $47.99/share, as a 25x multiple of taxed and diluted FY29 GAAP EPS of $5.45 discounted back to and (b) an NPV of $53.14/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) Vascepa commercial ramp-up and/or peak sales not meeting our projections; and (2) further competitive disruption of the omega-3 market by branded drugs or generics and/ or OTC supplements beyond our model." (8/1/2019)
  • 3. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating on AMRN shares after the company reported its 2Q19 financials, which came in at the higher end of its 7/2 pre-announcement; however, the key update is the fact management announced it believes an adcom is unlikely for Vascepa’s sNDA now given the close proximity to its PDUFA date. As we have discussed in previous notes, we believed the lack of an adcom would further de-risk Vascepa’s sNDA – so we see this update as an incremental positive and gets us more confident in sNDA approval. Given the high probability of approval, we believe investor focus is shifting to: (1) how Vascepa’s expanded label will read; (2) commercial execution in 2020 given its planned sales force expansion and whether or not 2020 Vascepa consensus sales estimates are too low; and (3) the potential timing and outcomes of Vascepa’s ongoing ANDA litigation." (7/31/2019)

Has Amarin been receiving favorable news coverage?

News headlines about AMRN stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amarin earned a coverage optimism score of -1.9 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Amarin.

Are investors shorting Amarin?

Amarin saw a decrease in short interest during the month of November. As of November 29th, there was short interest totalling 45,870,000 shares, a decrease of 5.2% from the November 14th total of 48,390,000 shares. Based on an average trading volume of 8,430,000 shares, the short-interest ratio is presently 5.4 days. Approximately 13.0% of the shares of the stock are sold short. View Amarin's Current Options Chain.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Square (SQ), Canopy Growth (CGC), Alibaba Group (BABA), Netflix (NFLX), Bank of America (BAC), Exelixis (EXEL) and Roku (ROKU).

Who are Amarin's key executives?

Amarin's management team includes the folowing people:
  • John F. Thero, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Craig B. Granowitz, Chief Medical Officer

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Pictet Asset Management Ltd. (0.53%), California Public Employees Retirement System (0.16%), Rhenman & Partners Asset Management AB (0.11%), Squarepoint Ops LLC (0.11%), Kornitzer Capital Management Inc. KS (0.09%) and Catalyst Capital Advisors LLC (0.08%). Company insiders that own Amarin stock include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Institutional Ownership Trends for Amarin.

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, State Street Corp, Tocqueville Asset Management L.P., First Midwest Bank Trust Division, Trellus Management Company LLC, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Tower Research Capital LLC TRC and Perkins Capital Management Inc.. Company insiders that have sold Amarin company stock in the last year include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Insider Buying and Selling for Amarin.

Which major investors are buying Amarin stock?

AMRN stock was bought by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Squarepoint Ops LLC, California Public Employees Retirement System, Virtu Financial LLC, Kornitzer Capital Management Inc. KS, Morse Asset Management Inc, Catalyst Capital Advisors LLC and Requisite Capital Management LLC. View Insider Buying and Selling for Amarin.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $24.12.

How big of a company is Amarin?

Amarin has a market capitalization of $8.62 billion and generates $229.21 million in revenue each year. The biopharmaceutical company earns $-116,440,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. View Additional Information About Amarin.

What is Amarin's official website?

The official website for Amarin is http://www.amarincorp.com/.

How can I contact Amarin?

Amarin's mailing address is Block C 77 Sir John Rogerson`s Quay Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]


MarketBeat Community Rating for Amarin (NASDAQ AMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  730 (Vote Outperform)
Underperform Votes:  441 (Vote Underperform)
Total Votes:  1,171
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Featured Article: Current Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel